J P Moore

Summary

Affiliation: Aaron Diamond AIDS Research Center
Country: USA

Publications

  1. ncbi request reprint Co-receptors for HIV-1 entry
    J P Moore
    The Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, New York, NY 10021, USA
    Curr Opin Immunol 9:551-62. 1997
  2. ncbi request reprint CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
    A Trkola
    The Aaron Diamond AIDS Research Centre, The Rockefeller University, New York 10016, USA
    Nature 384:184-7. 1996
  3. pmc Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
    A Trkola
    The Aaron Diamond AIDS Research Center, New York, USA
    J Virol 75:579-88. 2001
  4. pmc A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
    T Dragic
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Proc Natl Acad Sci U S A 97:5639-44. 2000
  5. pmc Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines
    A Trkola
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10021, USA
    J Virol 72:396-404. 1998
  6. pmc Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry
    T Dragic
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:279-85. 1998
  7. pmc Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1
    G E Rabut
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:3464-8. 1998
  8. pmc Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
    J M Binley
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 71:2799-809. 1997
  9. ncbi request reprint The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
    M Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    J Infect Dis 179:527-37. 1999
  10. pmc Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
    R I Connor
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:7501-9. 1998

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Co-receptors for HIV-1 entry
    J P Moore
    The Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, New York, NY 10021, USA
    Curr Opin Immunol 9:551-62. 1997
    ..The co-receptor functions of these proteins are inhibited by their natural alpha- and beta-chemokine ligands...
  2. ncbi request reprint CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
    A Trkola
    The Aaron Diamond AIDS Research Centre, The Rockefeller University, New York 10016, USA
    Nature 384:184-7. 1996
    ..Interference with HIV-1 binding to one or both of its receptors (CD4 and CCR-5) may be an important mechanism of virus neutralization...
  3. pmc Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140
    A Trkola
    The Aaron Diamond AIDS Research Center, New York, USA
    J Virol 75:579-88. 2001
    ..Thus CCR5-targeting agents such as PRO 140 can demonstrate potent and genetic-subtype-independent anti-HIV-1 activity...
  4. pmc A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
    T Dragic
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    Proc Natl Acad Sci U S A 97:5639-44. 2000
    ....
  5. pmc Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines
    A Trkola
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10021, USA
    J Virol 72:396-404. 1998
    ..Thus, for CCR5, the rank order for down-regulation was also RANTES, MIP-1beta, MIP-1alpha...
  6. pmc Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry
    T Dragic
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:279-85. 1998
    ..Thus, the gp120 and CC-chemokine binding sites on CCR5 are only partially overlapping, and the former site requires negatively charged residues in the amino-terminal CCR5 domain...
  7. pmc Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1
    G E Rabut
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:3464-8. 1998
    ..Tyrosine-15 is essential for viral entry irrespective of the test isolate. Substitutions at some of the other positions impair the entry of dualtropic HIV-1 isolates more than that of macrophagetropic ones...
  8. pmc Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1
    J M Binley
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 71:2799-809. 1997
    ....
  9. ncbi request reprint The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
    M Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    J Infect Dis 179:527-37. 1999
    ..In addition, given the reduction in levels of virus-specific immune responses, it would seem prudent to consider enhancing these responses using vaccine strategies prior to the withdrawal of antiviral therapy...
  10. pmc Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
    R I Connor
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 72:7501-9. 1998
    ....
  11. ncbi request reprint A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1
    C Spenlehauer
    Weill Medical College of Cornell University, New York, New York, USA
    Virology 280:292-300. 2001
    ..The luciferase end point simplifies the performance of neutralization and inhibitor-screening assays compared to the use of more conventional end points such as the detection of extracellular p24 antigen...
  12. pmc The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity
    A Trkola
    The Aaron Diamond AIDS Research Center, New York University School of Medicine, New York, USA
    J Virol 73:6370-9. 1999
    ....
  13. ncbi request reprint The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection
    J M Binley
    Weill Medical College of Cornell University, Dept of Microbiology and Immunology, New York, NY 10021, USA
    J Infect Dis 182:945-9. 2000
    ....
  14. ncbi request reprint HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
    T Dragic
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York 10016, USA
    Nature 381:667-73. 1996
    ..CC-CKR-5 is a second receptor for NSI primary viruses...
  15. pmc Human immunodeficiency virus type 1 strains of subtypes B and E replicate in cutaneous dendritic cell-T-cell mixtures without displaying subtype-specific tropism
    M Pope
    Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 10021, USA
    J Virol 71:8001-7. 1997
    ..Our findings do not support the conclusion that subtype E strains have a preferential tropism for DCs, suggesting that other explanations for the rapid heterosexual spread of subtype E strains in Asia should be considered...
  16. ncbi request reprint The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy
    J M Binley
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY 10016, USA
    J Infect Dis 181:1249-63. 2000
    ..Thus, CD4+ T cell responses can sometimes be regenerated if viral load is suppressed to allow some immune recovery and if antigenic stimulation is later provided...
  17. ncbi request reprint An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1
    J M Binley
    The Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    AIDS Res Hum Retroviruses 13:1007-15. 1997
    ..As most broadly neutralizing anti-gp120 antibodies recognize discontinuous epitopes, this skewing effect must be taken into account when interpreting studies using polyclonal sera...
  18. pmc Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells
    Y Zhang
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 10016, USA
    J Virol 74:6893-910. 2000
    ..The replication in human PBMC of SIV(rcm) (from a red-capped mangabey), a virus which uses CCR2 but not CCR5 for entry, was blocked by TAK-779, suggesting that CCR2 is indeed the paramount coreceptor for this virus in primary cells...
  19. ncbi request reprint New targets for inhibitors of HIV-1 replication
    J P Moore
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, New York 10021, USA
    Nat Rev Mol Cell Biol 1:40-9. 2000
    ..Among these, inhibitors of virus-cell fusion and integration are the most promising candidates...
  20. pmc Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
    J P Moore
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Ave, New York, NY 10021, USA
    J Virol 75:5721-9. 2001
  21. pmc Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein
    J P Moore
    Aaron Diamond AIDS Research Center, New York, New York 10016, USA
    J Virol 70:1863-72. 1996
    ..This analysis should be useful for understanding both the interaction of antibodies with the HIV-1 gp120 glycoprotein and neutralization of HIV-1...
  22. ncbi request reprint Effect of mutations in the V3 loop of HIV-1 gp120 on infectivity and susceptibility to proteolytic cleavage
    T F Schulz
    Chester Beatty Laboratories, Institute of Cancer Research, London, UK
    AIDS Res Hum Retroviruses 9:159-66. 1993
    ..Therefore, one would have to postulate the involvement of several cellular proteinases, or proteases with multiple specificities, in V3-based viral tropism...
  23. ncbi request reprint Binding of recombinant HIV-1 and HIV-2 SU glycoproteins to sCD4
    J P Moore
    J Acquir Immune Defic Syndr 4:442-3. 1991
  24. pmc Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom
    J Virol 65:1133-40. 1991
    ..At 4 degrees C, sCD4 neutralizes HIV infectivity by competitive inhibition alone. These findings may have implications for the HIV-CD4+ cell binding and fusion reactions and the mechanism by which sCD4 blocks infectivity...
  25. ncbi request reprint The role of the V3 loop of gp120 in HIV infection
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, UK
    AIDS 5:S21-33. 1991
  26. pmc Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom
    J Virol 66:235-43. 1992
    ....
  27. pmc Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding
    D Healey
    Academic Department of Genito Urinary Medicine, University College and Middlesex School of Medicine, London
    J Exp Med 172:1233-42. 1990
    ..These findings demonstrate that in addition to virus binding, CD4 may have an active role in membrane fusion...
  28. ncbi request reprint HIV-1 envelope protein gp120 expression by secretion in E. coli: assessment of CD4 binding and use in epitope mapping
    Y Morikawa
    NERC Institute of Virology and Environmental Microbiology, Oxford, U K
    J Virol Methods 29:105-13. 1990
    ..In addition, when used in conjunction with the truncated derivatives, rapid epitope mapping of anti-gp120 monoclonal antibodies is achieved using both Western-blot and ELISA formats...
  29. ncbi request reprint Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and of gp120 dissociation
    J P Moore
    Chester Beatty Laboratory, Institute of Cancer Research, London, England
    AIDS Res Hum Retroviruses 8:443-50. 1992
    ..The minimum temperatures for the sCD4 affinity transition and gp120 shedding are, therefore, similar and we suggest how the two processes might be related mechanistically...
  30. pmc Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding
    Q J Sattentau
    Academic Department of Genito Urinary Medicine, University College and Middlesex School of Medicine, London, United Kingdom
    J Exp Med 174:407-15. 1991
    ..We propose that these events occurring after CD4 binding are integral components of the membrane fusion reaction between HIV or HIV-infected cells and CD4+ cells...
  31. ncbi request reprint Kinetics of the HIV-CD4 interactions and virus-cell fusion
    P J Klasse
    AIDS 6:325-7. 1992
  32. pmc A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV-1 infection of CD4+ cells
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom
    J Virol 66:4784-93. 1992
    ..We opine that 5A8 blocks HIV-1 infection and fusion by interfering with conformational changes in gp120/gp41 and/or CD4 that are necessary for virus-cell fusion...
  33. ncbi request reprint Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site
    J A McKeating
    Chester Beatty Laboratory, Institute of Cancer Research, London, England
    AIDS Res Hum Retroviruses 8:451-9. 1992
    ..Our results indicate that the amino acids WQEVGKAMYA are exposed on the surface of recombinant gp120. Antibodies to these amino acids on recombinant gp120 compete for soluble CD4 binding in vitro, but only weakly neutralize HIV...
  34. ncbi request reprint Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, England
    AIDS Res Hum Retroviruses 6:1273-9. 1990
    ....
  35. ncbi request reprint Simple methods for monitoring HIV-1 and HIV-2 gp120 binding to soluble CD4 by enzyme-linked immunosorbent assay: HIV-2 has a 25-fold lower affinity than HIV-1 for soluble CD4
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, UK
    AIDS 4:297-305. 1990
    ..The affinity for sCD4 of HIV-2 viral gp120 is shown to be approximately 25-fold lower than that of HIV-1 gp120 (viral or recombinant)...
  36. ncbi request reprint Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, UK
    AIDS 4:307-15. 1990
    ....
  37. pmc A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1
    J P Moore
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016
    J Virol 67:3656-9. 1993
    ....
  38. pmc Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    A Trkola
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016, USA
    J Virol 70:1100-8. 1996
    ..consistent with this, antibodies able to block 2G12 binding to recombinant gp120 were not detected in significant quantities in 16 HIV-positive human serum samples...
  39. pmc Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation
    P Poignard
    Centre d immunologie de Marseille Luminy, France
    J Exp Med 183:473-84. 1996
    ....
  40. ncbi request reprint The role of CD4 in HIV binding and entry
    Q J Sattentau
    Centre d immunologie de Marseille Luminy, Marseille, France
    Philos Trans R Soc Lond B Biol Sci 342:59-66. 1993
    ..With the related lentiviruses HIV-2 and SIV, the CD4 induced molecular rearrangements in gp120 are more subtle, implying that there is a spectrum of responses to sCD4 binding...
  41. pmc Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains
    J P Moore
    Aaron Diamond AIDS Research Center, New York University School of Medicine, New York 10016
    J Virol 67:6136-51. 1993
    ..Soluble CD4 enhanced binding of one V2 MAb to oligomeric gp120 but not to monomeric gp120, perhaps by inducing conformational changes in the oligomer...
  42. pmc Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
    M Thali
    Department of Pathology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    J Virol 67:3978-88. 1993
    ..These results suggest that discontinuous, conserved epitopes proximal to the binding sites for both CD4 and anti-CD4 binding antibodies become better exposed upon CD4 binding and can serve as targets for neutralizing antibodies...
  43. ncbi request reprint Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure
    H J Ditzel
    Department of Immunology, Scripps Research Institute, La Jolla, CA 92037
    J Immunol 154:893-906. 1995
    ..The strategy of masking highly immunogenic epitopes with Abs to rescue a broader range of specific Abs from combinatorial libraries should be widely applicable...
  44. ncbi request reprint Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro
    Y Morikawa
    NERC Institute of Virology, Oxford, England
    AIDS Res Hum Retroviruses 6:765-73. 1990
    ..The crystallization of sCD4 purified from this source is reported...
  45. ncbi request reprint Dissociation of gp120 from HIV-1 virions induced by soluble CD4
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom
    Science 250:1139-42. 1990
    ..This may represent the initial stage in virus-cell and cell-cell fusion. Shedding of gp120 from virions induced by sCD4 may also contribute to the mechanism by which these soluble receptor molecules neutralize HIV-1...
  46. pmc Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding
    Q J Sattentau
    Centre d immunologie de Marseille Luminy, Marseille, France
    J Virol 67:7383-93. 1993
    ..This demonstrates that receptor binding to the outer envelope glycoprotein induces certain conformational changes which are common to all of these viruses and others which are restricted to cell line-passaged isolates of HIV-1...
  47. pmc Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding
    L Wu
    LeukoSite, Inc, Cambridge, Massachusetts 02142, USA
    J Exp Med 186:1373-81. 1997
    ..We conclude that the second extracellular loop of CCR5 is an ideal target site for the development of inhibitors of either chemokine or HIV-1 binding to CCR5...
  48. pmc Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion
    L G Abrahamyan
    Department of Molecular Biophysics and Physiology, Rush Medical College, Chicago, Illinois 60612, USA
    J Virol 77:5829-36. 2003
    ..The capture of this configuration of Env could yield a suitable antigen for vaccine development, and it may also be a target for pharmacological intervention against HIV-1 entry...
  49. pmc Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
    M B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:10892-905. 2001
    ..g., subtypes B, C, and E). The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design...
  50. pmc SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
    J M Strizki
    Schering-Plough Research Institute, Kenilworth, NJ 07033, USA
    Proc Natl Acad Sci U S A 98:12718-23. 2001
    ..On the basis of its novel mechanism of action, potent antiviral activity, and in vivo pharmacokinetic profile, SCH-C is a promising new candidate for therapeutic intervention of HIV infection...